Skip to Main Content

Arguing the Food and Drug Administration is precluding competition for biosimilar manufacturers, Boehringer Ingelheim has petitioned the agency to alter its interpretation of the word “strength” found in a federal law that has made it possible to sell these medicines.

The move reflects a wonky, behind-the-scenes dispute that, nonetheless, holds potentially great significance for the burgeoning growth of biosimilar treatments in the U.S., which is expected to reach $80 billion in aggregate sales over the next five years, according to one recent forecast.


At issue is an agency requirement that a biosimilar medicine must be the same strength as the brand-name biologic treatment. A biosimilar is a nearly identical variant of a brand-name biologic treatment that yields the same health outcome, but at a lower cost. Anticipation over lower prices has fueled demand for biosimilars, prompting several large pharmaceutical companies to target this market.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!